Capricor Therapeutics (NASDAQ: CAPR) net income
Capricor Therapeutics reported a net loss of $105.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $40.5m. Earnings per share were −$2.26.
Capricor Therapeutics's best year of the last 10 was fiscal 2017. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$105.0m | — | — | −$2.26 |
| 2024 | −$40.5m | — | −181.7% | −$1.15 |
| 2023 | −$22.3m | — | −88.5% | −$0.83 |
| 2022 | −$29.0m | — | −1,137.4% | −$1.18 |
| 2021 | −$20.0m | — | −8,175.9% | −$0.87 |
| 2020 | −$13.7m | — | −4,401.9% | −$0.88 |
| 2019 | −$7.6m | — | −760.4% | — |
| 2018 | −$15.2m | −724.8% | −908.9% | — |
| 2017 | $2.4m | — | 91.2% | $0.10 |
| 2016 | −$18.8m | — | −470.3% | −$1.01 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Capricor Therapeutics net income compared with its sector
By net income for its latest fiscal year, Capricor Therapeutics ranks 341st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 339th | Nkarta | −$104.1m | — |
| 340th | C4 Therapeutics | −$105.0m | −292.1% |
| 341st | Capricor Therapeutics | −$105.0m | — |
| 342nd | Oruka Therapeutics | −$105.4m | — |
| 343rd | AURA Biosciences | −$106.2m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Capricor Therapeutics
- How much did Capricor Therapeutics earn in fiscal 2025?
- Capricor Therapeutics reported a net loss of $105.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $40.5m.
- What are the earnings per share of Capricor Therapeutics?
- They were −$2.26 in fiscal 2025, compared with −$1.15 in fiscal 2024.
- What was the most profitable year for Capricor Therapeutics?
- Of its last 10 fiscal years, fiscal 2017, with $2.4m.
- Where does Capricor Therapeutics rank in its sector by net income?
- It ranks 341st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Capricor Therapeutics come from?
- From the annual report (Form 10-K) that Capricor Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Capricor Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Capricor Therapeutics: the Capricor Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.